Physician profile
Michael A Hart
NPI 1548235773
$2,799.66
in general payments reported to CMS, 2019-2025
24 companies · $406 in 2025
The $406 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $579 · 2023: $372 · 2024: $1,441 · 2025: $406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,104 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,104.41 |
| Education | $116.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,106.57 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $436.90 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $341.59 | 2021-2025 | Ozempic, Rybelsus |
| Phathom Pharmaceuticals, INC. | $154.74 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $141.63 | 2021-2024 | Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $86.46 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Edwards Lifesciences Corporation | $72.76 | 2023-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Pfizer INC. | $56.51 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.22 | 2021 | |
| Amgen INC. | $47.93 | 2024 | Otezla, Repatha |
| Otsuka America Pharmaceutical, INC. | $41.23 | 2024 | Rexulti |
| Abbott Laboratories | $33.83 | 2023-2024 | Eterna, Proclaim |
| Amarin Pharma, INC. | $26.74 | 2021 | |
| Inspire Medical Systems, INC. | $23.82 | 2025 | Inspire |
| Ethicon INC. | $22.29 | 2024 | Monarch Platform |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $21.46 | 2021 | |
| Hologic Sales and Service, LLC | $20.94 | 2024 | Aptima |
| Teleflex LLC | $19.46 | 2024 | Urolift |
| Exact Sciences Corporation | $18.93 | 2024 | Cologuard Collection Kit |
| Nevro Corp. | $18.36 | 2024 | Senza |
| Boston Scientific Corporation | $16.08 | 2021 | |
| Acella Pharmaceuticals, LLC | $15.24 | 2024 | NP Thyroid 60 |
| Currax Pharmaceuticals LLC | $14.23 | 2025 | Contrave |
| Merck Sharp & Dohme LLC | $13.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.